Central nervous system (CNS) leukemia after imatinib mesylate therapy for chronic myelogenous leukemia (CML)

被引：0
|
作者：
Solh, M. M.
Kantarjian, H.
O'Brien, S.
Giles, F.
Faderl, S.
Garcia-Manero, G.
Rios, M.
Shan, J.
Cortes, J.
Ravandi-Kashani, F.
机构：
[1] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate
    Vasantha Thavaraj
    Rachna Seth
    World Journal of Pediatrics, 2008, 4 : 145 - 147
  • [22] Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate
    Thavaraj, Vasantha
    Seth, Rachna
    WORLD JOURNAL OF PEDIATRICS, 2008, 4 (02) : 145 - 147
  • [23] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [24] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Mats Hardling
    Yuan Wei
    Lars Palmqvist
    Birgitta Swolin
    Dick Stockelberg
    Bengt Gustavsson
    Kerstin Ekeland-Sjöberg
    Hans Wadenvik
    Anne Ricksten
    Medical Oncology, 2004, 21 : 349 - 358
  • [25] Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
    Arora, Brijesh
    Kumar, Lalit
    Kumari, Mamta
    Sharma, Atul
    Wadhawa, Jyoti
    Kochupillai, V
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2005, 26 (02) : 5 - +
  • [26] The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
    Sneed, TB
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Rios, MB
    Bekele, BN
    Zhou, M
    Resta, D
    Wierda, W
    Faderl, S
    Giles, F
    Cortes, JE
    CANCER, 2004, 100 (01) : 116 - 121
  • [27] Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
    Kantarjian, HM
    Bueso-Ramos, CE
    Talpaz, M
    O'Brien, S
    Giles, F
    Faderl, S
    Wierda, W
    Rios, MB
    Shan, JQ
    Cortes, J
    CANCER, 2005, 104 (04) : 777 - 780
  • [28] Imatinib mesylate-sensitive discontinuation of imatinib blast crisis immediately after mesylate therapy in chronic myelogenous leukemia: Report of two cases
    Higashi, T
    Tsukada, J
    Kato, C
    Iwashige, A
    Mizobe, T
    Machida, S
    Morimoto, H
    Ogawa, R
    Toda, Y
    Tanaka, Y
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (03) : 275 - 278
  • [29] Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia
    Uchiyama, Michihiro
    Ikeda, Takashi
    LEUKEMIA RESEARCH, 2009, 33 (12) : 1723 - 1724
  • [30] Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
    Bueso-Ramos, CE
    Cortes, J
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Medeiros, LJ
    Kantarjian, H
    CANCER, 2004, 101 (02) : 332 - 336
12345